Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186628 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
A Phase 2 study of Mantle Cell Lymphoma and Leukemia, Mast-Cell, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00186628: Completed Phase 2 study of Mantle Cell Lymphoma and Leukemia, Mast-Cell, sponsored by Stanford University.
NCT00186628 is a Phase 2 study of Mantle Cell Lymphoma and Leukemia, Mast-Cell that has completed, run by Stanford University. The registered enrollment target is 36 participants, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186628, a Phase 2 study of Mantle Cell Lymphoma and Leukemia, Mast-Cell, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine if rituximab administered after allogeneic transplantation decreases the incidence of chronic graft-vs-host disease (cGvHD)
Primary Outcome
The cumulative percentage of participants who develop chronic graft-vs-host disease (cGvHD). Chronic cGvHD was defined as at least one instance of a clinically-accepted marker for cGvHD (see Filipovich, et al. Biology of Blood and Marrow Transplantation. 2005;11:945-955)
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Cyclosporine
- DRUG Mycophenylate mofetil
- PROCEDURE Total lymphoid irradiation
- DRUG Anti-thymoglobulin, rabbit (ATG, rabbit ATG)
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2005-06 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
What the finished NCT00186628 record still lists
NCT00186628 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 104-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Rituximab is the first listed.
NCT00186628 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00186628 about?
NCT00186628 is a clinical study titled "Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD". To determine if rituximab administered after allogeneic transplantation decreases the incidence of chronic graft-vs-host disease (cGvHD)
What is the current status of trial NCT00186628?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2005-06. Estimated completion is 2010-12.
What conditions does trial NCT00186628 study?
This clinical trial studies the following conditions: Mantle Cell Lymphoma, Leukemia, Mast-Cell.
What interventions are being tested in trial NCT00186628?
The interventions under investigation include: Rituximab (DRUG), Cyclosporine (DRUG), Mycophenylate mofetil (DRUG), Total lymphoid irradiation (PROCEDURE), Anti-thymoglobulin, rabbit (ATG, rabbit ATG) (DRUG).
Who is sponsoring clinical trial NCT00186628?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00186628 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mantle Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00186628's enrollment target sits among peer trials
36 60th of 102 higher than 41 of 102 other Mantle Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mantle Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
RECRUITING · Phase 2
-
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
RECRUITING · Phase 2
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
RECRUITING · Phase 2
-
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
RECRUITING · Phase 2
-
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia